Cite
Illingworth S, Di Y, Bauzon M, et al. Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus. Mol Ther Oncolytics. 2017;5:62-74doi: 10.1016/j.omto.2017.03.003.
Illingworth, S., Di, Y., Bauzon, M., Lei, J., Duffy, M. R., Alvis, S., Champion, B., Lieber, A., Hermiston, T., Seymour, L. W., Beadle, J., & Fisher, K. (2017). Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus. Molecular therapy oncolytics, 562-74. https://doi.org/10.1016/j.omto.2017.03.003
Illingworth, Sam, et al. "Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus." Molecular therapy oncolytics vol. 5 (2017): 62-74. doi: https://doi.org/10.1016/j.omto.2017.03.003
Illingworth S, Di Y, Bauzon M, Lei J, Duffy MR, Alvis S, Champion B, Lieber A, Hermiston T, Seymour LW, Beadle J, Fisher K. Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus. Mol Ther Oncolytics. 2017 Mar 29;5:62-74. doi: 10.1016/j.omto.2017.03.003. eCollection 2017 Jun 16. PMID: 28480328; PMCID: PMC5415321.
Copy
Download .nbib